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a b s t r a c t
Viremia kinetics directly inﬂuence the clinical course and transmission dynamics of DENV, but many
aspects of viral dynamics remain unknown. Non-human primates (NHP) have been used as a model
system for DENV infection for decades. Here, we identify papers with experimentally-infected NHP and
estimate the time to- and duration of viremia as well as estimate associations between these and
serotype, inoculating dose, viremia assay, and species of NHP. We estimate the time to viremia in rhesus
macaques to range from 2.63 to 3.32 days for DENV-2 and -1 and the duration to range from 3.13 to
5.13 days for DENV-4 and -2. We ﬁnd no differences between non-human primates for time to viremia or
duration, and a signiﬁcant negative relationship between inoculating dose and duration of viremia. These
results aid in understanding the transmission dynamics of sylvatic DENV non-human primates, an issue
of growing importance as dengue vaccines become available.
& 2014 The Authors. Published by Elsevier Inc.
Introduction
Knowledge of the kinetics of dengue fever virus (DENV) within
primate and non-primate hosts is a key to understanding trans-
mission dynamics and identifying populations at risk for infection
(Simmons et al., 2012). Due to logistical and ethical obstacles, few
studies have measured wildtype DENV viremia in humans over the
course of an infection. Thus, non-human primates have been the
major model system for comparison of viral dynamics between
DENV serotypes and strains as well as evaluation of dengue
therapeutics. While non-human primates differ from humans in
pathological responses to DENV infection, estimates of duration of
viremia that exist appear to be similar (Halstead et al., 1973;
Koraka et al., 2007), albeit with lower viral replication and
limitation of virus to a subset of those tissues infected in humans
(Zompi and Harris, 2012).
In addition to serving as a potential model for human diseases,
insight into the replication of DENV in non-human primates is
important in its own right. Four serotypes of sylvatic DENV have
been shown to circulate between non-human primates and
arboreal Aedes mosquitoes in Southeast Asia (Rudnick et al.,
1986) and sylvatic DENV serotype 2 is maintained in West Africa
(Diallo et al., 2003). These sylvatic viruses are ancestral to the four
serotypes of DENV that are currently transmitted between humans
by domestic and peridomestic Aedes (Vasilakis et al., 2011).
Populations living in areas surrounding sylvatic hotspots of DENV
transmission are at risk of infection (Cardosa et al., 2009; Franco
et al., 2011) from a transmission process that is poorly understood
(Vasilakis and Weaver, 2008). Importantly, it has recently been
discovered that sylvatic DENV infection in humans can produce
the most severe manifestation of dengue disease – dengue
hemorrhagic fever (Cardosa et al., 2009; Franco et al., 2011). In
the light of recent advances in DENV vaccines (Guy et al., 2010;
Durbin and Whitehead, 2010), sylvatic reservoirs may play a key
role in maintaining transmission over long time scales and may
continue to expose human populations to new, genetically distinct
viruses after human endemic transmission is controlled (Vasilakis
et al., 2011).
Isolations of sylvatic DENV have occurred at roughly 8 year
intervals in Senegal over the past 50 years (Diallo et al., 2003). The
key determinants of cycle length are largely unknown. As the
natural history of a pathogen has a direct inﬂuence on transmis-
sion dynamics (Keeling and Rohani, 2008) knowledge of the time
to detectable viremia and the length of viremia in non-human
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primates will be useful in ecological models of transmission
(Althouse et al., 2012) and may generate hypotheses for the
observed serotype-speciﬁc transmission patterns (Nisalak et al.,
2003) and clinical manifestations (Balmaseda et al., 2006; Halsey
et al., 2012) observed across DENV serotypes.
It is the goal of the present study to examine the kinetics of
DENV viremia in non-human primates through systematic review
and individual pooled analysis. We conducted a literature review
to identify experimental DENV infections of DENV-naïve monkeys.
We ﬁnd associations between time from inoculation to viremia
and duration of viremia and several covariates of interest using
mixed effects regression models. We report robust estimates of the
time to detectable viremia and the duration of viremia using
recently developed methods for handling doubly-interval cen-
sored data (Reich et al., 2009).
Results
Literature
Literature searches returned 1092 unique papers (Fig. 1). Of
these, 117 (11%) described dengue infection in non-human pri-
mates, 226 (21%) described observational/naturally occurring den-
gue infection in humans and not non-human primates, 91 (8%)
were about another disease, 125 (11%) had no abstracts, and 533
(49%) described experimental studies involving humans and
animal models (not involving NHP).
Fifty one published studies and three unpublished studies met the
criteria for inclusion and were included in the analysis (Table 1).
Thirty six included rhesus macaque (Macaca mulatta), 7 cynomolgus
macaques (Macaca fascicularis), 4 each with green monkeys (Chlor-
ocebus aethiops sabaeus) and owl monkeys (Aotus nancymaae),
3 chimpanzee (Pan troglodytes), 2 each with spider monkey (Ateles
geoffroyi) and pig-tailed macaques (Macaca nemestrina), and 1 each
with common marmoset (Callithrix jacchus), patas (Erythrocebus
patas), squirrel monkey (Saimiri sciureus), and White Handed Gibbon
(Hylobates lar). The bulk of the studies were vaccine trials/challenge
studies (34/51, 67%) the rest were experimental challenge trials (18/51
35%). 59 unique DENV genotypes were represented. 72 (10%) non-
human primates were infected with DENV-4 4328S, 43 (6.1%) with
DENV-2 S16803, and 40 (5.6%) with DENV-1 WP74 (see Supplemen-
tary Material). Table 2 reports numbers of non-human primates by
DENV serotype.
Associations with time to viremia and duration
Mixed effect models were ﬁt with a random effect for study
and were universally preferred over linear ﬁxed effect models by
AIC (see Supplementary Material). Intraclass correlation coefﬁ-
cients indicated strong heterogeneity by study (0.48, 95% CI: 0.37,
0.60) which could be due to differences among laboratories and
assays employed. Mixed effect models assume non-human pri-
mates are exchangeable within studies, and account for hetero-
geneity between studies. Mixed effect models employed here do
not take into account censoring, however only DENV-2 (p¼0.001)
and common marmoset samples (p¼0.03) were associated with
more censoring.
Tables 3 and 4 report the associations for serotype, log10
inoculating dose, assay, and species of non-human primate with
length of time to detectable viremia and duration of viremia in
mixed effect models. Both univariate (with only the covariate of
interest included) and multivariate (with all covariates included)
models were ﬁt. The multivariate models accounting for study
heterogeneity indicated the time to detectable viremia for DENV-1
was statistically signiﬁcantly longer than for DENV-4 and DENV-2
and -3 were not signiﬁcantly different from DENV-4. Time to
detectable viremia was statistically signiﬁcantly longer in patas
monkeys and marginally signiﬁcantly shorter in spider monkeys
than rhesus macaques; and time to detectable viremia was
signiﬁcantly shorter in those non-human primates assayed by
immunoﬂuorescence assays (IFA). Increasing log dose of inoculum
was statistically signiﬁcantly associated with shorter times to
detectable viremias (Table 3). Large study heterogeneity was
present, with the variance of the random intercept equal to 1 day.
Duration of viremia was statistically signiﬁcantly longer for
DENV-1 and -2 as compared to DENV-4 after accounting for study
heterogeneity. Duration for DENV-3 was not signiﬁcantly different
from DENV-4 (Table 4). Adjusting for study, species, assay, and
dose increased the difference in durations between DENV-1 and -2
and DENV-4. Changing the reference serotype to DENV-2 shows
DENV-1, -3, and -4 to have statistically signiﬁcantly shorter
durations of viremia than DENV-2 (see Supplementary Material).
Signiﬁcantly longer durations of viremia were observed when
assayed by RT-PCR and IFA compared to plaque-forming assays,
adjusting for study, species, assay, and dose. No signiﬁcant
differences in viremia duration were observed across species,
besides a signiﬁcant shortening in patas monkeys (however, only
3 patas monkeys were tested) and a marginally signiﬁcant short-
ening in green monkeys from rhesus monkeys. Duration of viremia
was negatively associated with dose of inoculum, with durations
decreasing by 0.44 days (95% CI: 0.18, 0.7) per log10 increase in
dose. Again, the variance of the random intercept was quite large
(2.32 days).
Estimates of time to detectable viremia and duration of viremia
In rhesus macaques the median time to detectable viremia of
DENV was 3.32 days (95% CI: 3.01, 3.65), 2.63 days (95% CI: 2.40,
2.89), 3.02 days (95% CI: 2.71, 3.34), and 3.23 days (95% CI: 2.99,
3.47) for DENV-1, -2, -3, and -4, respectively (Table 5 and Fig. 2).
1092 unique papers
1641 papers identified
549 duplicates
117 selected by title and abstract
66 excluded: 
Not dengue naive
No individual data
51 included for analysis
226 Natural Infection
91   Not dengue
125 No Abstract
533 Not NHP
Fig. 1. Flow chart of systematic review.
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The median duration of viremia was 4.67 days (95% CI: 4.27, 5.12),
5.13 days (95% CI: 4.82, 5.48), 3.22 days (95% CI: 2.83, 3.72), and
3.13 days (95% CI: 2.86, 3.46) for DENV-1, -2, -3, and -4, respec-
tively. As no signiﬁcant differences were observed in duration of
viremia between species (see above), estimates of duration were
pooled across all species. The median time to detectable viremia of
DENV was 3.23 days (95% CI: 3.00, 3.45), 2.44 days (95% CI: 2.22,
2.65), 2.89 days (95% CI: 2.67, 3.11), and 3.17 days (95% CI: 2.98,
3.37) for DENV-1, -2, -3, and -4, respectively (see Supplementary
Material). The median duration of viremia was 4.33 days (95% CI:
4.03, 4.67), 4.84 days (95% CI: 4.52, 5.15), 3.34 days (95% CI: 3.01,
3.68), and 3.24 days (95% CI: 3.01, 3.51) for DENV-1, -2, -3, and -4,
respectively (Figs. 3 and 4).
Discussion
The results of our meta-analysis indicate that the median time
to detectable viremia and duration of viremia of DENV was not
statistically signiﬁcantly different between non-human primate
species. In rhesus macaques (Macaca mulatta), median times to
detectable viremia ranged from 2.63 (95% CI: 2.40, 2.89) days for
Table 1
Summary of included studies. In table, primates studied are: rhesus macaque (Macaca mulatta), cynomolgus macaques (Macaca fascicularis), green monkeys (Chlorocebus
aethiops sabaeus), owl monkeys (Aotus nancymaae), chimpanzee (Pan troglodytes), spider monkey (Ateles geoffroyi), pig-tailed macaques (Macaca nemestrina), common
marmoset (Callithrix jacchus), patas (Erythrocebus patas), squirrel monkey (Saimiri sciureus), and White Handed Gibbon (Hylobates lar).
Study No. of primates Species Serotype Ref.
Anez (2009) 4 Rhesus macaque 4 Anez et al. (2009)
Angsubhakorn (1988) 4 Cynomolgus macaques, rhesus macaque 4 Angsubhakorn et al. (1988)
Bernardo (2008) 4 Cynomolgus macaques, rhesus macaque 1 Bernardo et al. (2008)
Bray (1996) 16 Rhesus macaque 1, 2, 4 Bray et al. (1996)
Butrapet (2002) 2 Cynomolgus macaques 1 Butrapet et al. (2002)
Chen (2007) 3 Cynomolgus macaques 1 Chen et al. (2007)
Clements (2010) 3 Rhesus macaque 2 Clements et al. (2010)
Durbin (2006), Unpub.a 6 Rhesus macaque 1, 2 Unpub.
Durbin (2007), Unpub.a 6 Rhesus macaque 1, 2 Unpub.
Durbin (2008), Unpub.a 6 Rhesus macaque 1, 2 Unpub.
Freire (2007) 26 Rhesus macaque 1, 2, 3 Freire et al. (2007)
Galler (2005) 5 Rhesus macaque 2 Galler et al. (2005)
Goncalvez (2007) 3 Rhesus macaque 4 Goncalvez et al. (2007)
Guirakhoo (2000) 8 Rhesus macaque 2 Guirakhoo et al. (2000)
Guzman (2003) 3 Cynomolgus macaques 4 Guzmán et al. (2003)
Halstead (1973) 119 Green monkey, patas, rhesus macaque 1, 2, 3, 4 Halstead et al. (1973)
Hanley (2004) 2 Rhesus macaque 4 Hanley et al. (2004)
Harrison (1977) 6 Chimpanzee, rhesus macaque 2 Harrison et al. (1977)
Hermida (2006) 3 Rhesus macaque 2 Hermida et al. (2006)
Houng (2000) 3 Rhesus macaque 2 Houng et al. (2000)
Kochel (2000) 5 Aotus 1 Kochel et al. (2000)
Kochel (2005) 18 Aotus 1 Kochel et al. (2005)
Lai (2007) 2 Rhesus macaque 4 Lai et al. (2007)
Marchette (1973) 27 Rhesus macaque 1, 2, 3, 4 Marchett et al. (1973)
Markoff (2002) 9 Rhesus macaque 1 Markoff et al. (2002)
Martin (2009) 12 Green monkey 2 Martín et al. (2009b)
Martin (2009) 6 Green monkey 2 Martín et al. (2009a)
Maves (2011) 6 Aotus 1 Maves et al. (2011)
Men (1996) 12 Rhesus macaque 4 Men et al. (1996)
Men (2000) 4 Rhesus macaque 2 Men et al. (2000)
Omatsu (2011) 20 Common marmoset 1, 2, 3, 4 Omatsu et al. (2011)
Onlamoon (2010) 6 Rhesus macaque 2 Onlamoon et al. (2010)
Pamungkas (2011) 14 Pig-tailed macaques (Macaca nemestrina) 3 Pamungkas et al. (2011)
Pletnev (2001) 4 Rhesus macaque 4 Pletnev et al. (2001)
Price (1968) 17 Spider monkey 1, 3, 4 Price et al. (1968)
Price (1973) 20 Spider monkey 1, 2, 3, 4 Price et al. (1973)
Price (1974) 25 Chimpanzee, cynomolgus macaques, 1, 4 Price et al. (1974)
Rhesus macaque, squirrel monkey
Putnak (1996) 3 Rhesus macaque 2 Putnak et al. (1996)
Putnak (2003) 9 Rhesus macaque 2 Putnak et al. (2003)
Raviprakash (2000) 5 Rhesus macaque 1 Raviprakash et al. (2000)
Raviprakash (2006) 5 Rhesus macaque 1, 2 Raviprakash et al. (2006)
Raviprakash (2008) 24 Rhesus macaque 1, 2, 3, 4 Raviprakash et al. (2008)
Rumyantsev (2006) 8 Rhesus macaque 4 Rumyantsev et al. (2006)
Scherer (1978) 10 Chimpanzee 1, 2, 3, 4 Scherer et al. (1978)
Schiavetta (2003) 15 Aotus 1, 2, 3, 4 Schiavetta et al. (2003)
Simmons (2006) 4 Rhesus macaque 2 Simmons et al. (2006)
Simmons (2010) 20 Rhesus macaque 1, 2, 3, 4 Simmons et al. (2010)
Sun (2006) 20 Rhesus macaque 1, 2, 3, 4 Sun et al. (2006)
Tarr (1976) 4 Rhesus macaque 2 Tarr and Lubiniecki (1976)
Valdes (2009) 3 Green monkey 2 Valdés et al. (2009)
Velzing (1999) 2 Cynomolgus macaques 2 Velzing et al. (1999)
Whitehead, variousb 84 Rhesus macaque 1, 2, 3, 4 Blaney et al. (2006)
Whitehead (1970) 33 White handed gibbon 1, 2, 3, 4 Whitehead et al. (1970)
Widjaja (2010) 16 Pig-tailed macaques (Macaca nemestrina) 1, 2, 3, 4 Widjaja et al. (2010)
a These studies are unpublished experiments by an author (APD) conducted in 2006, 2007, and 2008.
b These data were provided by Dr. S. Whitehead. The source studies are reviewed in Blaney et al. (2006).
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DENV-2 to 3.32 (95% CI: 3.01, 3.65) days for DENV-1 and median
duration of viremia from 3.13 (95% CI: 2.86, 3.46) days for DENV-4
to 5.13 (95% CI: 4.82, 5.48) days for DENV-2. These estimates are
shorter than those previously reported in humans. Tricou et al.
(2011) reported a median duration of viremia of 6.2 days (IQR 5.8–
7.2) for all serotypes and 6.8 days (IQR 6–7.3) for DENV-1. Vaughn
et al. (2000) reported a mean duration of viremia in humans of
5.5 days for primary DENV-1 infection and 4.6 days for primary
DENV-3 infection. Murgue et al. (2000) found a mean duration of
4.4 days for primary DENV infection in a cohort of French Poly-
nesian children. However, all three of these studies estimate the
duration of viremia in individuals hospitalized with dengue, and
thus likely not on the ﬁrst day of viremia. This would tend to
underestimate the true duration of viremia. Additionally, due to
selection of dengue cases based on severity (i.e., hospitalized
patients) the cases included in these studies may not be
representative of all dengue infections. The non-human primate
studies identiﬁed here skirt these two problems directly.
We found no statistically signiﬁcant differences in time to- or
duration of viremia between the 11 species of non-human pri-
mates studied here save for patas monkeys. Patas monkeys were
found to have signiﬁcantly longer times to detectable viremia and
shorter duration of viremia, however, only 3 patas were infected in
one study (Halstead et al., 1973). More measurements in patas
monkeys would be an important contribution as it is one of the
few species from which sylvatic DENV has been isolated (Diallo
et al., 2003). Similarly, spider monkeys had a marginally signiﬁ-
cantly shorter time to detectable viremia (p¼0.04) than rhesus
monkeys. Interestingly, the monkeys examined here included
several species of old and new world non-human primates,
otherwise expected to exhibit differing physiologic and immune
responses (Nunn et al., 2000).
Interestingly, the duration of DENV-4 viremia was signiﬁcantly
shorter than DENV-1 and -2 after adjusting for study, species,
assay and dose of inoculum. There has been clear demonstration of
differences in transmission patterns (Nisalak et al., 2003) and in
clinical manifestations (Balmaseda et al., 2006; Halsey et al., 2012)
across the four serotypes of DENV. Shorter duration of DENV-4
viremia may account for the reduced severity observed in this
serotype. Fried et al. (2010) found cases of dengue hemorrhagic
fever (DHF) to be twice as likely in secondary DENV-2 and
-3 infections than in secondary DENV-4. Conversely, we found
DENV-2 to be statistically signiﬁcantly longer than DENV-1, and
-3, and -4. Balmaseda et al. (2006) found nearly double the odds of
shock and internal hemorrhage with DENV-2 infection in out-
breaks of DENV in Nicaragua. Nisalak et al. (2003) found DENV-3
to be associated with severe outbreaks of dengue in hospitalized
cases in Bangkok, Thailand. Fox et al. (2011) found time to
undetectable DENV-2 NS1 protein to be signiﬁcantly longer than
DENV-1. Extended durations of viremia for DENV-2 and -3 may be
the cause of the increased severity of these infections and may be
Table 2
Summary of DENV infection by non-human primate species. Table reports numbers
of non-human primate species by infection with DENV serotypes 1–4.
Species DENV-1 DENV-2 DENV-3 DENV-4
Chimpanzee (Pan troglodytes) 2 6 2 12
Common marmoset (Callithrix jacchus) 1 17 1 1
Cynomolgus macaques
(Macaca fascicularis)
7 2 0 10
Green monkey
(Chlorocebus aethiops sabaeus)
1 23 1 0
Owl monkeys (Aotus nancymaae) 33 4 4 3
Patas (Erythrocebus patas) 1 2 0 0
Pig-tailed macaques
(Macaca nemestrina)
4 4 18 4
Rhesus macaque (Macaca mulatta) 97 155 75 139
Spider monkey (Ateles geoffroyi) 8 5 12 12
Squirrel monkey (Saimiri sciureus) 5 0 0 0
White handed gibbon (Hylobates lar) 7 9 8 9
Table 3
Associations with time to detectable viremia. Table reports the results of the univariate and multivariate mixed effects regression calculating associations between serotype,
species, viremia assay used, and log 10 inoculating dose and time to detectable viremia. Mixed effect models included random effect for study. Univariate estimates are
differences in days of viremia from the reference category of each model (denoted “Ref.”), and multivariate estimates are differences in days of viremia for each covariate
from rhesus monkeys infected with DENV-4 assayed using plaque count. P-values calculated using likelihood ratio tests. Estimates of the ﬁxed intercept (β0) and variance of
the random intercept are presented (s).
Covariate Univariate 95% CI P Multivariate 95% CI P
DENV-4 Ref. Ref.
DENV-1 0.53 (0.20, 0.86) 0.002 0.55 (0.22, 0.89) 0.001
DENV-2 0.09 (0.41, 0.22) 0.558 0.17 (0.49, 0.14) 0.254
DENV-3 0.20 (0.14, 0.54) 0.252 0.24 (0.10, 0.57) 0.153
Rhesus macaque (Macaca mulatta) Ref.
Chimpanzee (Pan troglodytes) 0.17 (1.10, 0.76) 0.730 0.30 (1.22, 0.63) 0.483
Common marmoset (Callithrix jacchus) 1.14 (3.15, 0.86) 0.214 0.61 (2.75, 1.53) 0.493
Cynomolgus macaques (Macaca fascicularis) 0.66 (0.18, 1.50) 0.132 0.74 (0.12, 1.60) 0.096
Green monkey (Chlorocebus aethiops sabaeus) 0.61 (0.32, 1.53) 0.301 1.23 (0.12, 2.35) 0.095
Owl monkeys (Aotus nancymaae) 0.21 (1.30, 0.89) 0.671 0.20 (1.47, 1.08) 0.777
Patas (Erythrocebus patas) 3.64 (2.13, 5.15) o0:001 3.89 (2.40, 5.39) o0.001
Pig-tailed macaques (Macaca nemestrina) 0.94 (2.40, 0.52) 0.162 0.50 (2.15, 1.15) 0.446
Spider monkey (Ateles geoffroyi) 1.29 (2.74, 0.15) 0.056 2.49 (5.20, 0.22) 0.040
Squirrel monkey (Saimiri sciureus) 0.35 (1.73, 1.03) 0.620 0.96 (2.36, 0.43) 0.162
White handed gibbon (Hylobates lar) 0.62 (1.35, 2.58) 0.508 0.27 (2.34, 1.80) 0.755
Plaque count Ref.
ELISA 0.75 (2.31, 0.82) 0.329 1.53 (3.51, 0.45) 0.161
FFA 0.02 (1.49, 1.52) 0.974 0.22 (1.41, 1.86) 0.746
IFA 0.75 (1.43, 0.07) 0.025 0.89 (1.74, 0.04) 0.016
RTPCR 0.67 (1.37, 0.03) 0.050 0.51 (1.39, 0.37) 0.170
Suckling mice 1.16 (2.34, 0.02) 0.043 0.64 (1.71, 2.99) 0.561
log 10 dose 0.15 (0.32, 0.01) 0.069 0.21 (0.39, 0.04) 0.021
Intercept (β0) 2.68 (1.63, 3.74) o0.001
Random effect (s) 0.99 (0, 2.93)
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the reason for sylvatic DENV-2 which is the only serotype to have
emerged in Africa from southeast Asia.
We found signiﬁcantly longer durations of viremia when
assayed using RT-PCR or immunoﬂuorescence as compared to
plaque-forming assays. This is most likely due to a higher
sensitivity of RT-PCR as compared to other, older methods for
determining viremia such as plaque counting and inoculation of
suckling mice. Though some of this may be due to detection of
viral RNA, and not actively replicating virus. More modern meth-
ods such as ELISA and focus-forming assays were not found to be
signiﬁcantly different from plaque-forming assays, but this could
be due to small sample sizes. The effect estimates for ELISA and
FFA were 1.34 and 0.27 days longer, respectively, adjusting for
study heterogeneity, serotype, species, and inoculating dose.
Importantly, these differences in detection of viremia were robust
to adjustment for study heterogeneity, which was considerable.
Intraclass correlation coefﬁcients indicated nearly half of the
observed variance was due to differences between studies. This
underlines the importance of using random effect models to
account for differences between studies, and using care when
interpreting results of viremia assays.
Surprisingly, increasing dose of innoculum was associated with
both shorter times to detectable viremia and shorter durations of
viremia. This phenomenon was observed by Martín et al. (2009a)
in green monkeys, in yellow fever virus (YFV) infections in rhesus
monkeys (Fox and Penna, 1943), chimeric YF-DENV vaccine in
cynomolgus macaques (Guirakhoo et al., 2004) and in humans
receiving a live, attenuated Japanese Encephalitis vaccine (Chimer-
iVax-JE) (Monath et al., 2003, 2002) and a live, attenuated West
Nile virus vaccine (Monath et al., 2006). It could be that a large
inoculating dose causes a rapid initial rise in viremia inducing a
stronger innate immune response leading to quicker clearance.
Studies in humans have found that higher peak viremia titers were
positively associated with more severe disease (Tricou et al., 2011;
Vaughn et al., 2000; Wang et al., 2003); however the evidence for
an association between the magnitude and duration of viremia
remains inconclusive. Vaughn et al. (2000) found the time from
peak viremia to clearance was more rapid in DHF cases than in DF
cases, while Fox et al. (2011) found no difference in rate of
clearance between DHF and DF.
Not all studies included in this meta-analysis reported daily
levels of viremia. Additional studies examining directly the rela-
tionship among inoculating dose, peak viremia and duration of
Table 4
Associations with duration of viremia. Table reports the results of the univariate and multivariate mixed effects regression calculating associations between serotype, species,
viremia assay used, and log 10 inoculating dose and duration of viremia. Mixed effect models included random effect for study. Univariate estimates are differences in days of
viremia from the reference category of each model (denoted “Ref.”), and multivariate estimates are differences in days of viremia for each covariate from rhesus monkeys
infected with DENV-4 assayed using plaque count. P-values calculated using likelihood ratio tests. Durations of DENV-1 and -2 viremia are signiﬁcantly longer than DENV-4
after adjusting for study, species, assay and log 10 dose. Estimates of the ﬁxed intercept (β0) and variance of the random intercept are presented (s).
Covariate Univariate 95% CI P Multivariate 95% CI P
DENV-4 Ref. Ref.
DENV-1 0.63 (0.17, 1.09) 0.008 0.74 (0.26, 1.21) 0.002
DENV-2 1.02 (0.58, 1.46) o0.001 1.21 (0.77, 1.65) o0.001
DENV-3 0.34 (0.81, 0.13) 0.151 0.30 (0.77, 0.17) 0.225
Rhesus macaque (Macaca mulatta) Ref.
Chimpanzee (Pan troglodytes) 0.16 (1.26, 1.57) 0.836 0.26 (1.06, 1.59) 0.624
Common marmoset (Callithrix jacchus) 0.15 (4.05, 3.76) 0.936 1.80 (5.09, 1.49) 0.185
Cynomolgus macaques (Macaca fascicularis) 0.23 (1.09, 1.55) 0.732 0.00 (1.24, 1.24) 0.941
Green monkey (Chlorocebus aethiops sabaeus) 1.36 (2.84, 0.12) 0.062 1.48 (3.08, 0.12) 0.050
Owl monkeys (Aotus nancymaae) 0.46 (2.54, 1.62) 0.637 1.29 (3.23, 0.66) 0.125
Patas (Erythrocebus patas) 2.07 (4.21, 0.06) 0.057 2.35 (4.45, 0.25) 0.026
Pig-tailed macaques (Macaca nemestrina) 0.40 (3.21, 2.42) 0.764 0.64 (3.16, 1.88) 0.514
Spider monkey (Ateles geoffroyi) 1.11 (3.91, 1.69) 0.400 0.34 (3.77, 4.46) 0.834
Squirrel monkey (Saimiri sciureus) 0.72 (2.72, 1.29) 0.470 1.39 (3.36, 0.59) 0.170
White handed gibbon (Hylobates lar) 0.00 (3.87, 3.86) 0.998 0.09 (3.09, 3.28) 0.932
Plaque count Ref.
ELISA 0.02 (2.81, 2.85) 0.987 1.34 (1.61, 4.30) 0.304
FFA 0.17 (2.59, 2.93) 0.889 0.27 (2.22, 2.75) 0.788
IFA 0.98 (0.29, 2.24) 0.110 1.34 (0.05, 2.64) 0.018
RTPCR 1.89 (0.59, 3.18) 0.004 2.52 (1.19, 3.85) o0.001
Suckling mice 0.16 (2.39, 2.06) 0.880 0.37 (3.92, 3.18) 0.807
log 10 dose 0.40 (0.65, 0.14) 0.002 0.44 (0.69, 0.18) o0.001
Intercept (β0) 5.00 (3.47, 6.53) o0.001
Random effect (s) 2.32 (0, 5.30)
Table 5
Summary of DENV virus kinetics in rhesus macaques. Table reports median days to
viremia and duration of viremia with 95% bootstrap conﬁdence intervals for 5th,
25th, 50th, 75th, and 95th percentile.
Serotype Percentile Time to viremia Duration
Days (95% CI) Days (95% CI)
1 5th 1.43 (1.20, 1.68) 2.02 (1.73, 2.44)
n¼97 25th 2.35 (2.08, 2.64) 3.31 (2.97, 3.76)
50th 3.32 (3.01, 3.65) 4.67 (4.27, 5.12)
75th 4.69 (4.28, 5.11) 6.59 (6.01, 7.18)
95th 7.73 (6.89, 8.57) 10.82 (9.51, 12.12)
2 5th 0.98 (0.82, 1.18) 2.24 (1.98, 2.59)
n¼155 25th 1.76 (1.55, 2.00) 3.65 (3.35, 4.00)
50th 2.63 (2.40, 2.89) 5.13 (4.82, 5.48)
75th 3.95 (3.67, 4.22) 7.21 (6.73, 7.70)
95th 7.06 (6.48, 7.64) 11.76 (10.48, 13.01)
3 5th 1.30 (1.07, 1.57) 1.03 (0.84, 1.33)
n¼75 25th 2.14 (1.85, 2.41) 2.02 (1.73, 2.41)
50th 3.02 (2.71, 3.34) 3.22 (2.83, 3.72)
75th 4.26 (3.78, 4.74) 5.14 (4.56, 5.84)
95th 6.99 (5.91, 8.13) 10.05 (8.70, 11.58)
4 5th 1.44 (1.32, 1.58) 1.10 (0.95, 1.31)
n¼139 25th 2.32 (2.16, 2.51) 2.04 (1.83, 2.32)
50th 3.23 (2.99, 3.47) 3.13 (2.86, 3.46)
75th 4.49 (4.12, 4.84) 4.82 (4.38, 5.28)
95th 7.22 (6.48, 7.89) 8.96 (7.96, 10.00)
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viremia are necessary, as well as studies investigating the effects of
preexisting immunity on time to viremia and duration.
Our methods separately accounted for the two largest potential
sources of bias: random effect models accounted for study
heterogeneity and doubly-interval censored survival analysis
accounted for the large amount of censoring (right-, left- and
both) present in reported days of non-human primate viremia.
While the random effect model did not take into account the
effects of censoring, the amount of censoring only differed in
DENV-2 and common marmoset samples, and inferences drawn
from them are useful for examining associations between covari-
ates of interest and the time to detectable viremia and duration of
viremia. Even though the random effect model accounts for most
of the heterogeneity between studies, some caution must still be
used when interpreting the results of the associations as some
residual confounding may exist from remaining heterogeneity
between studies. Finally, while all efforts were made to ﬁnd all
studies reporting non-human primate viremia, it is possible that
some studies were missed, or that some data were not published
(Dickersin et al., 1990).
Our study provides estimates of the times to detectable viremia
and durations of DENV-1–4 viremia in multiple non-human
primate species, both Old World and New World, and identiﬁes
how these differ across serotype, viremia assay, non-human
primate species and inoculating dose. Few if any studies have
directly compared DENV infection in multiple non-human pri-
mates. Our results further understanding of within host DENV
replication kinetics which are especially important in how they
inﬂuence transmission dynamics. In the light of new dengue
vaccine trials (Halstead, 2012; Sabchareon et al., 2012), sylvatic
DENV infection in non-human primates could provide a source of
infectious introductions. An accurate and thorough understanding
of the sylvatic cycle of dengue, including the roles of the various
non-human primate species in transmission, may allow prediction
of epidemics within non-human primates and thereby lessen the
impact of spillover on humans living in areas of overlap with non-
human primate hosts. Our results also are important in parame-
terizing dynamic models of dengue (Althouse et al., 2012), and
further understanding of DENV transmission dynamics in general,
including differences in serotype-speciﬁc cycles.
Methods
Systematic review
We searched PubMed, Web of Science and Google scholar for
articles containing the terms “dengue primate viremia infection”,
“dengue viremia primates”, “dengue viremia monkey”, “dengue
vaccine primates”, and “dengue infection primates”. We narrowed
our focus to primary infections where details on the infecting virus
were reported. Our inclusion criteria were:
1. The non-human primate must be DENV naïve at the time of
experimental infection (including free of exposure to experi-
mental vaccines).
2. The challenge serotype (DENV-1–4) and the speciﬁc virus
strain (with passage number, if applicable) must be clearly
identiﬁed and the dosage of virus stated (in plaque forming
units [PFU]), and
3. The presence of viremia must be reported on a day-by-day
basis, at least two time points, either in a graph or table, and
not in a summary statistic. This does not preclude monkeys
bled sporadically (e.g., every other day).
Additional (unpublished) studies were identiﬁed through expert
consultation. Abstracts were doubly reviewed (BMA, DATC).
Time to event data
A survival analytic approach was used to determine time-to-
event (viremia or clearance). If more than one method for asses-
sing viremia was used, the method with the higher sensitivity was
reported (though multiple methods were compared). Data were
classiﬁed as fully observed, single- or doubly-interval censored.
Observations were fully observed if the non-human primates
were bled and found not to be viremic before and after being
found viremic. If non-human primates were found to be viremic
on the ﬁrst or last sample taken, then the data point was assumed
single-interval censored. If non-human primates were viremic on
both the ﬁrst and last sample, then the data point was assumed
doubly-interval censored imposing left and right boundaries of
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DENV−1
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Day
N
on
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Fig. 2. Days of viremia for primates. Figure shows the days of viremia for each non-
human primate stratiﬁed by DENV serotype. Blue bars indicate DENV negative
blood samples and red bars indicate positive samples. White indicates no samples.
Data were sorted by DENV serotype, then by days of viremia.
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Fig. 3. Time to detectable viremia for DENV in rhesus macaque. Figure shows estimates of the time to detectable viremia for DENV-1–4 in rhesus primates. Black lines
indicate estimates from full dataset and light colored lines indicate bootstrap replicates. Gray lines indicate the 5th, 25th, 50th, 75th and 95th quantiles.
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Fig. 4. Duration of DENV infection in rhesus macaque. Figure shows estimates of the duration of infection for DENV-1–4 in rhesus primates. Black lines indicate estimates
from full dataset and light colored lines indicate bootstrap replicates. Gray lines indicate the 5th, 25th, 50th, 75th and 95th quantiles.
inoculation and 16 days (estimates are insensitive to this number,
see Supplementary Material). Observations missing or negative
surrounded by two viremic samples were assumed to be viremic.
Methods for analyzing doubly-interval censored data have been
developed previously (Reich et al., 2009). We estimate the time to
detectable viremia and the duration of viremia, both of which we
assume are log-normally distributed (see Supplementary Mate-
rial). We stratify by DENV serotype and compute bootstrap
conﬁdence intervals.
Associations with time to viremia and duration
To explore the potential association between length of time to
detectable viremia and duration of viremia, linear and random
effect models were ﬁt with time to viremia or duration as the
outcome, a random effect for study and serotype, inoculating dose,
viremia assay, and species of non-human primate as potential
covariates of interest (Fitzmaurice et al., 2011). As these models do
not directly take into account the effects of censoring, we test for
differences censoring between covariates. Linear and mixed effect
models are compared using the Akaike information criterion (AIC)
(Burnham et al., 2002).
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